JP6663866B2 - リジン特異的なデメチラーゼ−1の阻害剤 - Google Patents

リジン特異的なデメチラーゼ−1の阻害剤 Download PDF

Info

Publication number
JP6663866B2
JP6663866B2 JP2016575768A JP2016575768A JP6663866B2 JP 6663866 B2 JP6663866 B2 JP 6663866B2 JP 2016575768 A JP2016575768 A JP 2016575768A JP 2016575768 A JP2016575768 A JP 2016575768A JP 6663866 B2 JP6663866 B2 JP 6663866B2
Authority
JP
Japan
Prior art keywords
optionally substituted
pharmaceutically acceptable
compound
acceptable salt
formula
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
JP2016575768A
Other languages
English (en)
Japanese (ja)
Other versions
JP2017525668A5 (cg-RX-API-DMAC7.html
JP2017525668A (ja
Inventor
チェン,ヤング,ケイ.
カノウニ,トウフィケ
ニエ,チェ
スタッフォード,ジェフリー,アラン
ヴィール,ジェイムス,マービン
Original Assignee
セルジーン クオンティセル リサーチ,インク.
セルジーン クオンティセル リサーチ,インク.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by セルジーン クオンティセル リサーチ,インク., セルジーン クオンティセル リサーチ,インク. filed Critical セルジーン クオンティセル リサーチ,インク.
Publication of JP2017525668A publication Critical patent/JP2017525668A/ja
Publication of JP2017525668A5 publication Critical patent/JP2017525668A5/ja
Application granted granted Critical
Publication of JP6663866B2 publication Critical patent/JP6663866B2/ja
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D417/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4151,2-Diazoles
    • A61K31/4161,2-Diazoles condensed with carbocyclic ring systems, e.g. indazole
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425Thiazoles
    • A61K31/427Thiazoles not condensed and containing further heterocyclic rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445Non condensed piperidines, e.g. piperocaine
    • A61K31/4523Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D417/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/04Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D417/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/06Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D471/00Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04Ortho-condensed systems
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D471/00Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/10Spiro-condensed systems
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D487/00Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04Ortho-condensed systems
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D519/00Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Polyamides (AREA)
JP2016575768A 2014-07-03 2015-06-29 リジン特異的なデメチラーゼ−1の阻害剤 Expired - Fee Related JP6663866B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201462020886P 2014-07-03 2014-07-03
US62/020,886 2014-07-03
PCT/US2015/038345 WO2016003917A1 (en) 2014-07-03 2015-06-29 Inhibitors of lysine specific demethylase-1

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2019029856A Division JP6768857B2 (ja) 2014-07-03 2019-02-21 リジン特異的なデメチラーゼ−1の阻害剤

Publications (3)

Publication Number Publication Date
JP2017525668A JP2017525668A (ja) 2017-09-07
JP2017525668A5 JP2017525668A5 (cg-RX-API-DMAC7.html) 2018-05-31
JP6663866B2 true JP6663866B2 (ja) 2020-03-13

Family

ID=55019883

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2016575768A Expired - Fee Related JP6663866B2 (ja) 2014-07-03 2015-06-29 リジン特異的なデメチラーゼ−1の阻害剤
JP2019029856A Expired - Fee Related JP6768857B2 (ja) 2014-07-03 2019-02-21 リジン特異的なデメチラーゼ−1の阻害剤

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2019029856A Expired - Fee Related JP6768857B2 (ja) 2014-07-03 2019-02-21 リジン特異的なデメチラーゼ−1の阻害剤

Country Status (29)

Country Link
US (3) US9902719B2 (cg-RX-API-DMAC7.html)
EP (2) EP3164380B1 (cg-RX-API-DMAC7.html)
JP (2) JP6663866B2 (cg-RX-API-DMAC7.html)
KR (1) KR102475498B1 (cg-RX-API-DMAC7.html)
CN (2) CN108530424B (cg-RX-API-DMAC7.html)
AU (1) AU2015284383B2 (cg-RX-API-DMAC7.html)
BR (1) BR112017000043A2 (cg-RX-API-DMAC7.html)
CA (1) CA2954049A1 (cg-RX-API-DMAC7.html)
CL (1) CL2016003422A1 (cg-RX-API-DMAC7.html)
CO (1) CO2017000549A2 (cg-RX-API-DMAC7.html)
CY (1) CY1125127T1 (cg-RX-API-DMAC7.html)
DK (2) DK3511319T3 (cg-RX-API-DMAC7.html)
EA (2) EA201891526A3 (cg-RX-API-DMAC7.html)
EC (1) ECSP17006821A (cg-RX-API-DMAC7.html)
ES (2) ES2907676T3 (cg-RX-API-DMAC7.html)
FI (1) FI3511319T3 (cg-RX-API-DMAC7.html)
HR (2) HRP20220414T1 (cg-RX-API-DMAC7.html)
HU (2) HUE062558T2 (cg-RX-API-DMAC7.html)
IL (2) IL249881B (cg-RX-API-DMAC7.html)
LT (2) LT3511319T (cg-RX-API-DMAC7.html)
MX (2) MX395534B (cg-RX-API-DMAC7.html)
PL (2) PL3511319T3 (cg-RX-API-DMAC7.html)
PT (2) PT3511319T (cg-RX-API-DMAC7.html)
RS (2) RS64423B1 (cg-RX-API-DMAC7.html)
SA (1) SA517380651B1 (cg-RX-API-DMAC7.html)
SG (2) SG11201610975RA (cg-RX-API-DMAC7.html)
SI (2) SI3164380T1 (cg-RX-API-DMAC7.html)
SM (2) SMT202200136T1 (cg-RX-API-DMAC7.html)
WO (1) WO2016003917A1 (cg-RX-API-DMAC7.html)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20180284095A1 (en) 2015-06-12 2018-10-04 Oryzon Genomics, S.A. Biomarkers associated with lsd1 inhibitors and uses thereof
WO2017013061A1 (en) 2015-07-17 2017-01-26 Oryzon Genomics, S.A. Biomarkers associated with lsd1 inhibitors and uses thereof
CA3017411C (en) 2016-03-15 2024-06-25 Oryzon Genomics, S.A. Combinations of lsd1 inhibitors for use in the treatment of solid tumors
EP3430015B9 (en) 2016-03-16 2025-12-31 Oryzon Genomics, S.A. METHODS FOR DETERMINING THE ENGAGEMENT OF A KDM1A TARGET AND CORRESPONDING USEFUL CHEMOPROBE
US10150754B2 (en) 2016-04-19 2018-12-11 Celgene Quanticel Research, Inc. Histone demethylase inhibitors
US20190256930A1 (en) 2016-11-03 2019-08-22 Oryzon Genomics, S.A. Biomarkers for determining responsiveness to lsd1 inhibitors
AU2018309372B2 (en) 2017-08-03 2024-08-15 Oryzon Genomics, S.A. Methods of treating behavior alterations
AU2019319971B2 (en) * 2018-08-10 2024-11-28 Navire Pharma, Inc. 6-(4-amino-3-methyl-2-oxa-8-azaspiro(4.5)decan-8-yl)-3-(2,3-dichlorophenyl)-2-methylpyrimidin-4(3h)-one derivatives and related compounds as ptpn11 (shp2) inhibitors for treating cancer
CA3127993A1 (en) * 2019-02-01 2020-08-06 Hanmi Pharm. Co., Ltd. Imidazopyridine derivative compounds and use of same
JP7532386B2 (ja) 2019-02-01 2024-08-13 ハンミ ファーマシューティカルズ カンパニー リミテッド イミダゾピリジン誘導体化合物及びその用途
CN113631164A (zh) 2019-03-20 2021-11-09 奥莱松基因组股份有限公司 使用kdm1a抑制剂如化合物伐菲德司他治疗注意缺陷多动症的方法
AU2020242302B2 (en) 2019-03-20 2025-10-30 Oryzon Genomics, S.A. Methods of treating borderline personality disorder
JP2022546908A (ja) 2019-07-05 2022-11-10 オリゾン・ゲノミクス・ソシエダッド・アノニマ Kdm1a阻害剤を使用した小細胞肺がんの個別化された処置のためのバイオマーカーおよび方法
US11360505B2 (en) 2020-02-11 2022-06-14 Simmonds Precision Products, Inc. Distributed network time synchronization
CN114105950B (zh) * 2020-08-31 2022-09-06 南京明德新药研发有限公司 吡唑类化合物及其应用
TWI834127B (zh) * 2021-03-11 2024-03-01 大陸商南京明德新藥研發有限公司 噻吩類化合物及其應用
US20240216357A1 (en) * 2021-03-24 2024-07-04 Sichuan Huiyu Pharmaceutical Co., Ltd. Polycyclic compound and application thereof
AU2022254484A1 (en) 2021-04-08 2023-11-09 Oryzon Genomics, S.A. Combinations of lsd1 inhibitors for treating myeloid cancers
CN116102533A (zh) * 2021-11-11 2023-05-12 中国科学院上海药物研究所 一种芳杂环类化合物及其应用
WO2023217758A1 (en) 2022-05-09 2023-11-16 Oryzon Genomics, S.A. Methods of treating malignant peripheral nerve sheath tumor (mpnst) using lsd1 inhibitors
JP2025516648A (ja) 2022-05-09 2025-05-30 オリゾン・ゲノミクス・ソシエダッド・アノニマ Lsd1阻害薬を用いるnf1変異腫瘍の治療法
KR20250109775A (ko) 2022-11-24 2025-07-17 오리존 지노믹스 에스.에이. 암 치료를 위한 lsd1 억제제 및 메닌 억제제의 조합

Family Cites Families (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE1963188A1 (de) 1969-12-17 1971-06-24 Bayer Ag Neue Cyanphenyl-1,4-dihydropyridinderivate
WO2002026718A2 (en) * 2000-09-29 2002-04-04 Millennium Pharmaceutical, Inc. Bicyclic pyrimidin-4-one based inhibitors of factor xa
US7365069B2 (en) * 2002-04-10 2008-04-29 Bexel Pharmaceuticals Inc. Pyrimidone derivatives
JP2005170792A (ja) * 2002-11-22 2005-06-30 Mitsubishi Pharma Corp L−プロリン誘導体およびその医薬としての用途。
EP1695969A4 (en) * 2003-12-11 2008-11-26 Mitsubishi Tanabe Pharma Corp ALPHA-AMINO-ACID DERIVATIVES AND THEIR USE AS MEDICINE
WO2006073167A1 (ja) * 2005-01-07 2006-07-13 Ono Pharmaceutical Co., Ltd. ピロリジン誘導体
PL372332A1 (pl) * 2005-01-19 2006-07-24 ADAMED Sp.z o.o. Nowe związki, pochodne kwasu 3-fenylopropionowego
WO2006129181A2 (en) * 2005-06-03 2006-12-07 Orchid Research Laboratories Limited Preparation of 4-pyrimidone derivatives for treating inflammatory diseases
PT1924561E (pt) * 2005-09-01 2013-01-16 Lilly Co Eli Módulo de cabeça de impressão tendo uma fiada solta e controlador de impressora para lhe fornecer dados
JP2007197324A (ja) * 2006-01-23 2007-08-09 Toray Ind Inc 2,4,5−置換−1,3−アゾール誘導体
TW200815428A (en) * 2006-08-15 2008-04-01 Wyeth Corp Oxazolidone derivatives as PR modulators
US7652018B2 (en) 2006-08-15 2010-01-26 Wyeth Llc Imidazolidin-2-one derivatives useful as PR modulators
PE20081803A1 (es) 2007-03-09 2008-12-11 Wyeth Corp Sintesis y caracterizacion de la forma ii polimorfica de 4-(2-(4,4-dimetil-2-oxooxazolidin-3-il)tiazol-4-il)benzonitrilo
CL2008002793A1 (es) * 2007-09-20 2009-09-04 Cgi Pharmaceuticals Inc Compuestos derivados de amidas sustituidas, inhibidores de la actividad de btk; composicion farmaceutica que los comprende; utiles en el tratamiento del cancer, trastornos oseos, enfermedades autoinmunes, entre otras
WO2009132310A1 (en) * 2008-04-25 2009-10-29 Wisconsin Alumni Research Foundation Inhibitors of udp-galactopyranose mutase thwart mycobacterial growth
US20130096160A1 (en) * 2010-04-14 2013-04-18 Secretary, Department Of Health And Human Services Arylthiazolyl piperidines and related compounds as modulators of survival motor neuron (smn) protein production
WO2012009475A1 (en) * 2010-07-14 2012-01-19 Oregon Health & Science University Methods of treating cancer with inhibition of lysine-specific demethylase 1
NZ629453A (en) * 2012-03-06 2016-04-29 Lupin Ltd Thiazole derivatives as alpha 7 nachr modulators
FI3080100T3 (fi) * 2013-12-11 2023-03-15 Celgene Quanticel Res Inc Lysiinispesifisen demetylaasi-1:n estäjät
BR112016018691A2 (pt) * 2014-02-14 2017-08-08 Univ British Columbia Compostos do domínio de ligação ao dna (dbd) de receptor de andrógeno humano como terapêuticos e métodos para seu uso
HRP20220096T1 (hr) * 2014-05-01 2022-04-15 Celgene Quanticel Research, Inc. Inhibitori lizin specifične demetilaze-1
FR3020945B1 (fr) 2014-05-16 2016-05-06 Oreal Composition pour colorer les fibres keratiniques comprenant une base d'oxydation et un coupleur heteroaryle particulier
LT3160956T (lt) * 2014-06-27 2020-09-10 Celgene Quanticel Research, Inc. Lizinui specifinės demetilazės-1 inhibitoriai
JP6525422B2 (ja) * 2014-07-03 2019-06-05 セルジーン クオンティセル リサーチ,インク. リジン特異的なデメチラーゼ−1の阻害剤

Also Published As

Publication number Publication date
IL249881A0 (en) 2017-03-30
FI3511319T3 (fi) 2023-07-20
EA201891526A2 (ru) 2018-12-28
JP2019108346A (ja) 2019-07-04
CO2017000549A2 (es) 2017-04-20
MX395534B (es) 2025-03-25
IL272130B (en) 2021-03-25
JP6768857B2 (ja) 2020-10-14
WO2016003917A1 (en) 2016-01-07
KR102475498B1 (ko) 2022-12-07
CL2016003422A1 (es) 2017-11-10
US10100046B2 (en) 2018-10-16
RS64423B1 (sr) 2023-09-29
SI3164380T1 (sl) 2022-06-30
MX2017000168A (es) 2017-05-01
ES2907676T3 (es) 2022-04-26
CN106795103B (zh) 2019-07-12
PL3164380T3 (pl) 2022-04-04
EP3511319B1 (en) 2023-05-03
ECSP17006821A (es) 2017-03-31
DK3164380T3 (da) 2022-03-28
EA033698B1 (ru) 2019-11-18
US20190002456A1 (en) 2019-01-03
HRP20220414T1 (hr) 2022-05-27
KR20170018100A (ko) 2017-02-15
CN106795103A (zh) 2017-05-31
LT3511319T (lt) 2023-08-25
HRP20230595T1 (hr) 2023-09-15
EA201891526A3 (ru) 2019-05-31
IL272130A (en) 2020-03-31
CY1125127T1 (el) 2024-02-16
MX376207B (es) 2025-03-07
EA201790085A1 (ru) 2017-08-31
CN108530424A (zh) 2018-09-14
LT3164380T (lt) 2022-06-27
CA2954049A1 (en) 2016-01-07
SA517380651B1 (ar) 2020-09-30
BR112017000043A2 (pt) 2018-07-17
EP3164380A4 (en) 2018-07-18
PT3511319T (pt) 2023-06-29
JP2017525668A (ja) 2017-09-07
MX2020010900A (es) 2022-09-13
SG11201610975RA (en) 2017-01-27
AU2015284383A1 (en) 2017-02-02
US20180127408A1 (en) 2018-05-10
HUE062558T2 (hu) 2023-11-28
PT3164380T (pt) 2022-03-02
SMT202200136T1 (it) 2022-05-12
AU2015284383B2 (en) 2019-04-18
ES2948782T3 (es) 2023-09-19
US20170129882A1 (en) 2017-05-11
PL3511319T3 (pl) 2023-09-11
EP3164380A1 (en) 2017-05-10
CN108530424B (zh) 2021-10-01
EP3511319A1 (en) 2019-07-17
IL249881B (en) 2020-01-30
US9902719B2 (en) 2018-02-27
HUE058852T2 (hu) 2022-09-28
SG10201802501RA (en) 2018-05-30
EP3164380B1 (en) 2022-02-09
DK3511319T3 (da) 2023-07-31
SI3511319T1 (sl) 2023-10-30
SMT202300205T1 (it) 2023-09-06
RS63074B1 (sr) 2022-04-29

Similar Documents

Publication Publication Date Title
JP6663866B2 (ja) リジン特異的なデメチラーゼ−1の阻害剤
CN106659914B (zh) 赖氨酸特异性脱甲基酶-1的抑制剂
CN106660987B (zh) 赖氨酸特异性脱甲基酶-1的抑制剂
JP6525422B2 (ja) リジン特異的なデメチラーゼ−1の阻害剤
HK1231860B (en) Inhibitors of lysine specific demethylase-1
HK1231860A1 (en) Inhibitors of lysine specific demethylase-1

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20180410

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20180411

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20181203

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20181129

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20190221

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20190701

RD02 Notification of acceptance of power of attorney

Free format text: JAPANESE INTERMEDIATE CODE: A7422

Effective date: 20190808

RD04 Notification of resignation of power of attorney

Free format text: JAPANESE INTERMEDIATE CODE: A7424

Effective date: 20190809

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20191025

RD13 Notification of appointment of power of sub attorney

Free format text: JAPANESE INTERMEDIATE CODE: A7433

Effective date: 20191028

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A821

Effective date: 20191028

A911 Transfer to examiner for re-examination before appeal (zenchi)

Free format text: JAPANESE INTERMEDIATE CODE: A911

Effective date: 20191119

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20200121

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20200217

R150 Certificate of patent or registration of utility model

Ref document number: 6663866

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

LAPS Cancellation because of no payment of annual fees